Thinking of joining a study?

Register your interest

NCT05549947 | Completed | Moderate to Severe Atopic Dermatitis


Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis
Sponsor:

Shanghai Hengrui Pharmaceutical Co., Ltd.

Brief Summary:

This trial was designed to evaluate the efficacy and safety of SHR-1819 injection in patients with atopic dermatitis

Condition or disease

Moderate to Severe Atopic Dermatitis

Intervention/treatment

SHR1819

Placebo

Phase

Phase 2

Study Type : Interventional
Estimated Enrollment : 158 participants
Masking: Single
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacokinetics of SHR-1819 Injection in Adults With Moderate to Severe Atopic Dermatitis
Actual Study Start Date : October 8, 2022
Estimated Primary Completion Date : September 15, 2023
Estimated Study Completion Date : November 23, 2023
Arm Intervention/treatment

Experimental: Treatment group A:SHR-1819

Drug: SHR1819

Experimental: Treatment group B:SHR-1819

Drug: SHR1819

Experimental: Treatment group C:SHR-1819

Drug: SHR1819

Placebo Comparator: Treatment group D:placebo

Drug: Placebo

Ages Eligible for Study: 18 Years to 75 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Criteria
Inclusion Criteria
  • Subjects voluntarily sign informed consent forms prior to the commencement of any proceedings related to the study, are able to communicate smoothly with the investigator, understand and are willing to complete the study in strict compliance with the requirements of this clinical research protocol;
  • Age 18 to 75 years old (inclusive) at the time of signing the informed consent form, regardless of gender;
  • Have atopic dermatitis at the time of screening (according to the 2014 American College of Dermatology Guidelines) and have a course of at least 1 year before screening;
  • At the screening and baseline periods, EASI ≥ 16, IGA ≥3, BSA ≥ 10 %
  • The average daily peak pruritus (itch) numerical evaluation scale (P-NRS) score for the first 7 days of randomization ≥4 points (at least 4 days of daily peak pruritus P-NRS scores need to be collected);
  • According to the investigators, topical TCS treatment was poor or intolerant within 6 months prior to screening
Exclusion Criteria
  • Pregnant or lactating women
  • Major surgeries are planned for the duration of the study
  • History of previous atopic corneal conjunctivitis involving the cornea
  • History of clinically significant diseases (e.g., circulatory system abnormalities, endocrine system abnormalities, neurological disorders, hematologic disorders, immune system disorders, psychiatric disorders, and metabolic instability) that the researcher believes that participation in the study poses a risk to the safety of the subject or that the disease/illness worsens during the study period will affect the effectiveness or safety analysis.
  • Subjects have had or are currently clinically significant diseases or abnormalities
  • Screening for people with a history of heavy alcohol consumption or substance abuse in the 3 months prior to screening
  • The drug has been used in the previous 6 months
  • Screening of subjects with malignancy within the first 5 years (except completely cured cervical cancer in situ and non-metastatic cutaneous squamous cell carcinoma or basal cell carcinoma)
  • Other comorbid (or co-occurring) skin disorders may be affected in the study evaluation
  • Any cause that the researchers believe would prevent the participants from participating in the study

Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis

Location Details


Please Choose a site



Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations


Not yet recruiting

China, Shanghai

Huashan Sub-Hospital of Fudan University

Shanghai, Shanghai, China, 200040

Loading...